Emami Limited
Emami is engaged in manufacturing & marketing of personal care & healthcare products with an enviable portfolio of household brand names such as BoroPlus, Navratna, Fair and Handsome, Zandu Balm, Kesh King, Zandu Pancharishta, Mentho Plus Balm and others.(Source : 201903 Annual Report Page No: 193)
What Emami files
- Others62
- Investor Meet36
- Pledging33
- Updates16
- Important15
- Board Meeting14
Emami reported resilient performance with consolidated revenue up 15% to ₹1,039 crore. Domestic business surged 20% (12% like-to-like, 8% volume growth), while International Business saw a 12% decline due to West Asia disruptions. Despite higher input costs, EBITDA grew 6% to ₹226 crore, and PBT increased 4% to ₹195 crore....
Emami's Q4FY26 results show revenue dipped 4% to ₹925 Cr, with PAT at ₹143 Cr. Full-year FY26 revenue was ₹3780 Cr, with PAT at ₹775 Cr. Crucially, the domestic non-summer business grew a healthy 11% in Q4, showing core strength despite a weak summer portfolio and a 5% drop in...
**1. Business Performance:** Emami delivered resilient FY25 performance: consolidated revenues +6%, PAT +11%. Key brands (Navratna, Dermicool, BoroPlus, Zandu Healthcare) drove growth. Q3FY26 grew 11%, recovering from H1 challenges; international business also expanded. **2. Growth Drivers or Strategy:** Strategic focus: diversifying core brands from niche to mainstream, brand rejuvenation (Kesh...
Emami delivered a strong Q3FY26! Revenue from operations jumped 10% YoY to ₹1,152 Cr. Domestic business grew 11% (9% volume), while international sales climbed 9%. Profit After Tax surged 15% to ₹319 Cr. EBITDA rose 13% to ₹384 Cr, expanding margins by 110 bps to 33.4%. Growth was fueled by...
Emami's Board met to discuss financial results for the quarter and half-year. **Business Performance:** Q2 consolidated revenue declined 10% YoY to ₹799 Cr, with Profit After Tax (PAT) falling 30% to ₹148 Cr and EBITDA down 29% to ₹179 Cr. This was largely due to temporary trade disruptions from GST...